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Abstract
Background: A new LC–MS/MS method for the simultaneous determination of lamivudine, zidovudine, and
nevirapine in human plasma is developed using column-coupling technique.
Method: Labeled compound of respective analyte was used as an internal standard. After extraction from 100 μL
plasma by solid phase extraction method, analytes were separated on a C18 column coupled with a cation
exchange column. Total run time was 4.5 min. A tandem mass spectrometric detection was conducted using
multiple reaction monitoring under positive ionization mode with an electrospray ionization interface. The method
was validated as per the FDA guidelines over the concentration range of 9.47–1466.67 ng/mL for lamivudine, 10.
32–1600.00 ng/mL for zidovudine, and 15.05–2426.67 ng/mL for nevirapine.
Results: Precision was in the range 0.86–5.77 (intraday) and 1.92–8.19 (interday) while accuracy was 93.25–104.36 %
(intraday) and 96.83–103.28 % (interday). Stabilities of stock in aqueous solutions and in plasma were also determined.
Conclusion: The method can be applied to the pharmacokinetic study of a combination treatment.
Background
Acquired immunodeficiency syndrome (AIDS) due to
infection of human immunodeficiency virus type 1
(HIV-1) is one of the deadliest diseases in recent years
causing death of millions of people across the world.
Due to rapid development of resistance of this virus
against the single anti-HIV drugs and also the dose-
dependent side effects produced by these drugs leads to
the treatment failure within 1 year after the initiation of
antiretroviral therapy (Ledergerber et al. 1999). In recent
years, combination therapy has become the standard line
of treatment to manage acquired immunodeficiency syn-
drome (AIDS) (De Clercq 2002). Effective combination
therapy generally used for treatment of AIDS contains
two nucleoside reverse transcriptase inhibitors (NRTI)
and a non-nucleoside reverse transcriptase inhibitor
(NNRTI), or a single protease inhibitor (PI) (Gallant
2002). The NRTIs like lamivudine [(2R, cis)-4- amino-l-
(2-hydroxymethyl-l, 3-oxathiolan-5-yl)-(lH)-pyrimidin-2-
one)] and zidovudine (3-azido- 3-deoxythymidine) can
inhibit the replication of HIV-1 and HIV-2 in different
kinds of cells. However, lamivudine has very low cellular
cytotoxicity and is generally less potent than zidovudine
in inhibiting HIV-1 and HIV-2 replication in vitro
(Richman et al. 1987; Goodman and Gillman’s 2001; Lai
et al. 1998; Van Leth et al. 2004). Nevirapine (11-cyclo-
propyl-5, 11-dihydro-4-methyl-6H-dipyrido- [3, 2-b: 2,
3 e] (Ledergerber et al. 1999; Richman et al. 1987)
diazepin-6-one), on the other hand, belongs to a class
of NNRTI and can inhibit reverse transcriptase of HIV-
1 (HIV-1 RT) (Van Leth et al. 2004). Due to the syner-
gistic action of different classes of antiretroviral drugs,
the survival of HIV patients is prolonged to a great
extent and thus such combination therapy, called highly
active antiretroviral therapy (HAART), is now consid-
ered as a first-line therapy.
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Several LC–MS/MS methods have been reported for
the determination of lamivudine, zidovudine, and nevira-
pine in biological samples either alone or in combination
with other drugs (Font et al. 1999; Kenney et al. 2000; Per-
eira et al. 2000; Chi et al. 2003; Mistri et al. 2007; Elase et
al. 2010; Gehrig et al. 2007; Murali Krishna et al. 2012;
Zhou et al. 2010). However, these methods had their own
problems in respect to the sample preparation, gradient
elution, run time, polarity switching, etc. A LC–MS/MS
method for the simultaneous determination of lamivudine,
zidovudine, and nevirapine in human plasma was recently
reported (Valluru Rajani et al. 2013). This method was val-
idated as per FDA regulations and successfully applied to
a clinical pharmacokinetic study involving oral administra-
tion of a combination of the three drugs to healthy male
volunteers. However, this method requires larger plasma
sample. Moreover, in this method, both lamivudine and zi-
dovudine were eluting in the void volume. We developed
a new and sensitive LC–MS/MS method for simultaneous
estimation of these three drugs in human plasma. This
method is validated as per FDA regulations (US Food and
Drug Administration, Center for Drug Evaluation and Re-




Lamivudine (purity: 99.8 %), zidovudine (purity: 98.9 %),
and nevirapine (purity: 100 %) were purchased from Vivan
Life Sciences, Mumbai, India. Lamivudine 13C 15N2 D2
(purity: 99.13 %), zidovudine 13C D3 (purity: 99.33 %), and
nevirapine D4 (purity: 98.07 %) used as internal standards
were also from Vivan Life Sciences, Mumbai, India.
Methanol (HPLC-grade), ammonium acetate, disodium
hydrogen phosphate, and formic acid of the highest purity
grade were purchased locally. Milli-Q purified water
(Millipore, Milford, MA) was used throughout the study.
Strata-X, 33 μ, polymeric reversed phase 30 mg/1 ml
cartridges were procured from Phenomenex.
Plasma lots collected in house were used for the
experiments.
Preparation of solutions
Stock solution of individual analyte (200 μg/ml) was
prepared in methanol. This concentration was then
corrected by taking into account its potency and actual
amount weighed.
The stock solutions of lamivudine and zidovudine were
then diluted together with 50 % methanol in water to
concentration ranges of 472.85 to 73,333.43 ng/ml (lami-
vudine) and 515.84 to 80,000.00 ng/ml (zidovudine).
Similarly nevirapine stock solution (200 μg/ml) was
further diluted with 50 % methanol in water to concen-
tration ranges of 752.27 to 121,333.33 ng/ml.
Preparation of calibration standards
To prepare calibration curve standards, 20 μl of the
diluted samples of lamivudine and zidovudine was added
to 960 μl of K2EDTA pooled plasma. Then, 20 μl of each
dilution of nevirapine was added. Final concentration
ranges were 9.46 to 1466.67 ng/ml for lamivudine, 10.32
to 1600.00 ng/ml for zidovudine, and 15.05 to 2426.67 ng/
ml for nevirapine, respectively. All these bulk spiked
samples were stored below −20 °C in aliquot of 200 μl.
Preparation of quality control samples
Stock solutions of analytes were diluted as mentioned
above with 50 % methanol in water to obtain the concen-
tration ranges of 478.52 to 56666.67 ng/ml for lamivudine,
523.56 to 62000.00 ng/ml for zidovudine, and 752.27 to
121333.33 ng/ml for nevirapine. Nine hundred sixty micro-
liters of K2EDTA pooled plasma was then spiked with 20 μl
of each of quality control dilution of lamivudine and
zidovudine mixture and nevirapine solution.
Final concentration ranges were 9.63 to 1146.90 ng/ml
for lamivudine, 10.44 to 1243.43 ng/ml for zidovudine,
and 15.24 to 1845.48 ng/ml for nevirapine.
Preparation of solution of internal standards
Lamivudine 13C 15N2 D2, zidovudine 13C D3, and nevira-
pine D4 were used as internal standards. Two hundred mi-
crograms per milliliter stock solutions in methanol were
prepared individually for each of them. The respective stock
solution was diluted with 50 % methanol in water to obtain
a mixture of internal standards containing lamivudine
(1 μg/ml), zidovudine (1 μg/ml), and nevirapine (2 μg/ml).
Sample preparation
Fifty microliters of internal standard mixture (lamivudine
13C 15N2 D2 + zidovudine 13C D3 + nevirapine D4) was
added to all RIA vials except blank. One hundred microli-
ters of sample was then added to respectively labeled RIA
vials. Five hundred microliters of 100-mM anhydrous
disodium hydrogen phosphate was added to all samples
and mixed by vortex. After centrifugation at 4000 rpm for
5 min in refrigerated centrifuge at 4 °C, the samples were
then subjected to solid phase extraction (SPE).
SPE cartridges (Strata-X, 33 μ, polymeric reversed phase
30 mg/1 ml) were conditioned with 1 ml each of methanol
and Milli-Q water. The cartridges were then transferred to
respectively labeled RIA tubes, and the samples were loaded
onto the SPE column by centrifuging at 1000 rpm for
5 min. Washing was performed with 1 ml each of Milli-Q
water and then 5 % methanol in water (v/v), respectively, by
centrifuging at 2000 rpm for 5 min. Finally, the cartridges
were transferred to fresh labeled RIA tubes and eluted with
1 ml of methanol: water mixture (80:20, v/v) by centrifuga-
tion at 500 rpm for 5 min. Vials were loaded into auto-
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sampler for chromatographic operation. Sample processing
was done under yellow monochromatic light.
Chromatography
Ten microliters of sample was injected on a reversed phase
column (Synergi, 4 μ, Polar-RP 80A, 100 × 4.6 mm) which
is connected in series with a cation exchange column (Bio-
basic SCX, 50 × 4.6 cm, 5 μm). An isocratic mobile phase
(10 mM ammonium acetate in 0.2 % formic acid: Metha-
nol:30:70, v/v) was used at a flow rate of 1.0 ml/min with
splitter in Shimadzu HPLC attached to API 4000 Mass
spectrometer (Applied Biosystems, USA). The reversed
phase column was maintained at 40 °C in the column oven
whereas the SCX column was kept at ambient temperature.
The run time was 4.8 min.
Mass spectrometry
Electrospray ionization (ESI) interface operated in positive
ionization mode was used for the multiple reaction moni-
toring (MRM). By infusing diluted stock solutions of each
analyte, the operational conditions were optimized as
follows (Table 1).
Source temperature was set at 250 °C. Nebulizer gas
(GS1) and auxiliary gas (GS2) flows were 45 and 55 psi,
respectively. Quadrupoles Q1 and Q3 were set on unit
resolution. Acidic mobile phase (due to addition of formic
acid) has improved the protonation of all compounds and
has shown a positive impact on signal intensities.
MRM transitions monitored were as follows: m/z
230.1→ 112.1 (LAM), m/z 235.0→ 115.1 (LAM 13C
15 N2 D2), m/z 268.2→ 127.1 (ZDV), m/z 272.2→ 131.1
(ZDV 13C D3), m/z 267.1→ 226.1 (NEV), and m/z
271.2→ 230.2 (NEV D4).
Sample concentrations were calculated by linear
regression analysis using the analyst software 1.5.1. Data
was processed by peak area ratio. The concentration of
unknown was calculated from the equation (Y = mx + c)
using regression analysis of spiked plasma calibration




Specific and effective sample clean-up procedures are
required for sensitive and selective LC–MS/MS assays
for the determination of very low concentration levels of
pharmaceutical targets present in biological samples.
Three methods, e.g., protein precipitation (PPT), liquid–li-
quid extraction (LLE), and solid-phase extraction (SPE),
are generally used for preparing biological specimen.
Protein precipitation method using organic solvent is the
simplest one but the chances of matrix effect prevail.
Since the extraction efficiency for highly polar xanalytes is
lower, the LLE method is ruled out for lamivudine and zi-
dovudine. We therefore used SPE technique using reverse
phase cartridge for sample extraction. Moreover, this tech-
nique was further simplified by introducing centrifugation
step during washing/elution as we could centrifuge a large
number of samples at the same time to save time. Since
there were no evaporation and reconstitution steps, time
requirement for this method was much less compared to
that described by Kumar et al. (Valluru Rajani et al. 2013).
This technique was shown to be robust, provided clean
samples, and gave good and reproducible recoveries of all
analytes and IS. The extraction recovery of analytes was
determined by comparing peak areas from plasma
samples (n = 6) spiked before extraction with those from
aqueous samples. The mean overall recoveries across QC
levels (with precision) were 76.09 ± 2.953 % (3.88 %) for
LAM, 94.38 ± 4.605 % (4.88 %) for ZDV, and 97.30 ±
2.956 % (3.04 %) for NVP (Table 2). The recovery of each
IS was more than 74 % (data not shown).
During optimization of chromatographic conditions,
we noticed that both LAM and ZDV being highly polar
molecules were not retained in the RP column and were
eluting either in the void volume or very early. These
short retention times were also noticed in the methods
described earlier by others (Murali Krishna et al. 2012;
Valluru Rajani et al. 2013). This warrants attention about
the possibility of improper separation of analytes as well
as the matrix effect. Keeping this in mind, we used

















Lamivudine 400 30 10 20 12 08 5500 30
Lamivudine
IS
400 30 10 20 12 08 5500 30
Zidovudine 400 20 10 17 07 08 5500 30
Zidovudine
IS
400 35 10 13 07 08 5500 30
Nevirapine 400 40 10 35 12 08 5500 30
Nevirapine
IS
400 40 10 35 17 08 5500 30
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column coupling technique in which we passed the elute
from C18 column through SCX column consecutively.
Nevirapine being a lyophilic molecule bound tightly with
the RP column and eluted late. To make the method
simpler, we used the same mobile phase for both the
columns instead of different mobile phases. The total
run time was only 4.5 min. The short run time is also
ideally suited for being considered in high throughput
analysis. This method provided good separation of
analytes as well as internal standards. The retention
times for lamivudine, zidovudine, and nevirapine were
3.28, 2.23, and 2.88 min, respectively. The retention
times for internal standards were 3.27 min (LAM),
2.2 min (ZDV), and 2.85 min (NVP), respectively.
Method validation
The current LC–MS/MS assay was validated as per FDA
guidelines for specificity, linearity, intra- and interday
precision and accuracy, and stability.
Selectivity
Selectivity of the method was evaluated in eight individ-
ual human K2 EDTA plasma lots along with one lipemic
and one hemolytic lot. Negligible interferences were ob-
served at the retention times of analytes and internal
standards when peak responses in blank lots were com-
pared against the response of spiked LLOQ containing
IS mixtures. Representative chromatograms in Fig. 1a–c
(blank plasma) and Fig. 2a–c (blank plasma spiked with
analytes/IS) demonstrate the selectivity of the method.
Linearity and sensitivity
Eight-point calibration curves were prepared with con-
centration ranging from 9.505 to 1473.327 ng/ml for
LAM, 10.373 to 1607.896 ng/ml for ZDV, and 15.066 to
2418.780 ng/ml for NVP. The peak-area ratio (y) of
analytes to internal standards was plotted against the
nominal concentration (x) of analytes to determine the
linearity of each calibration curve. Excellent linearity was
achieved with correlation coefficients greater than 0.999
for all validation batches.
The concentrations of calibration standards were back
calculated to obtain the accuracy of each calibration
point. The ranges of the calibration points’ accuracy for
LAM, ZDV, and NVP were 98.4–102.1, 97.7–103.7, and
97.7–101.7 %, respectively.
Precision and accuracy at the LLOQs were respectively
7.12 and 96.83 % for LAM, 8.19 and 98.64 % for ZDV, and
3.84 and 102.40 % for NVP. The LLOQs of the method is
9.634 ng/ml for LAM, 10.445 ng/ml for ZDV, and
15.236 ng/ml for NVP, respectively, which are at par with
the reported ones (Murali Krishna et al. 2012; Valluru
Rajani et al. 2013). Limits of detection were found to be
2.376 ng/ml (for LAM; signal to noise ratio > 26.780),
2.593 ng/ml (for ZDV; signal to noise ratio > 13.605), and
3.767 ng/ml (for NVP; signal to noise ratio > 154.045).
This indicates that this method is sensitive enough for a
pharmacokinetic study. Moreover, the good signal-to-
noise obtained at this concentration indicates that the
LLOQ of the method can be lowered further or the
volume of plasma can be decreased. This further widens
the scope of this method even to the pediatric patients.
Precision and accuracy
Precision and accuracy for intra- and interday batches
for all analytes were determined by six replicate analyses
of QC samples (n = 6) at four different concentration-
s—lower limit of quantification (LLOQ), low quality
control (LQC), middle quality control (MQC), and high
quality control (HQC). The respective concentrations
for LAM, ZDV, and NVP were 9.634, 10.445, and
15.236 ng/ml for LLOQ, 27.526, 29.842, and 44.292 ng/
ml for LQC, 458.761, 497.370, and 738.192 ng/ml for
MQC, and 1146.902, 1243.426, and 1845.480 ng/ml for
HQC. Results of precision and accuracy were presented
in Table 3. The intraday and interday precision were
within 8.4 % for all analytes. The assay accuracy was
89.2–106.4 % of the nominal values. The accuracy of the
assay was expressed by [(mean observed concentration)/
(spiked concentration)] × 100 %, and precision was
evaluated by relative standard deviation (RSD).
Matrix effect
Matrix effect was investigated by extracting blank
plasma from eight different sources, including one
hemolytic and one lipemic lot. One hundred microliters
of blank plasma from each lot was processed as per the
procedure mentioned in sample preparation. Aqueous
Table 2 Recovery of analytes in spiked human plasma






















Lamivudine 33,232 24,856 74.80 556,655 411,977 74.01 1,299,965 1,033,108 79.47
Zidovudine 7586 7007 92.37 127,866 116,498 91.11 297,863 296,796 99.64
Nevirapine 52,217 52,567 100.67 889,635 854,959 96.10 2,192,647 2,085,960 95.13
an = 6
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Fig. 1 a Blank plasma for lamivudine and its IS. b Blank plasma for zidovudine and its IS. c Blank plasma for nevirapine and its IS
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Fig. 2 a Chromatogram of lamivudine and its IS. b Chromatogram of zidovudine and its IS. c Chromatogram of nevirapine and its IS
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solution of individual analyte either at LQC or HQC
level was added to each of the final eluent. These sam-
ples were considered as post-extracted samples (pres-
ence of matrix).
Similarly, the aqueous solution of individual analyte ei-
ther at LQC or HQC level was prepared with the elution
solvent and was considered as aqueous samples (absence
of matrix). Six replicates each of aqueous samples were
injected along with post-extracted samples of LQC and
HQC.
Individual analyte area response and IS area response of
each post-extracted sample were compared with the mean
analyte area response and mean IS area response of the
aqueous sample, respectively. The matrix effect was calcu-
lated via the formula: Matrix effect (%) = A2/A1 × 100(%),
where A1 = response of aqueous concentrations and A2 is
the response of post-extracted concentrations.
Average (n = 6) matrix factor ranges from 94.66–
101.09 % with a CV range of 1.21–4.24 % for all analytes
at LQC level and internal standards. At HQC level, the
range was 101.99–103.97 with a CV range of 1.66–
2.09 % which is within the accepted limit (% CV ≤ 15)
(Table 4).
Dilution integrity
Dilution integrity of the method was evaluated after di-
luting twofold and fourfold with interference free human
plasma. Six replicates of these samples were processed
and analyzed against a set of freshly spiked calibration
standards. The upper concentration limits were shown
to be extendable up to 2325.98 ng/mL for LAM,
2515.90 ng/mL for ZDV, and 3690.96 ng/mL for NVP by
dilution with blank plasma. The mean back calculated
concentrations for twofold and fourfold dilution samples
were within 92.18–111.60 % with a % CV of ≤3.43 for all
three analytes.
Carryover effect
Carryover effect was evaluated in order to evaluate the
cleaning ability of rinsing solution used for the injection
needle and port. This avoids any carryover of injected
sample in subsequent runs. The experiment was car-
ried out by placing samples in the following order:
LLOQ of individual analyte, blank plasma, and upper
limit of quantitation (ULOQ) of individual analyte
and blank plasma. No carryover was observed during
the experiment.
Stability
Stability evaluations were performed in both aqueous-
and matrix-based samples. For aqueous solution, both
short-term and long-term stabilities were determined
as follows:
Table 3 Accuracy and precision of analysis in the quality-control samples
Intraday Interday
Analyte QC sample Actual conc. (ng/ml) Estimated conc. (ng/ml) Accuracy (%) % CV Estimated conc. (ng/ml) Accuracy (%) % CV
Lamivudine LLOQ 9.63 10.05 104.36 3.01 9.33 96.83 7.12
LQC 27.53 28.06 101.95 2.01 27.92 101.43 3.20
MQC 458.76 457.46 99.72 2.26 457.49 99.72 1.92
HQC 1146.90 1152.58 100.49 1.67 1157.65 100.94 2.49
Zidovudine LLOQ 10.44 9.81 93.95 5.77 10.30 98.64 8.19
LQC 29.84 27.83 93.25 3.52 29.59 99.15 5.59
MQC 497.37 483.61 97.23 2.56 494.18 99.36 2.75
HQC 1243.43 1227.03 98.68 2.42 1244.60 100.09 3.42
Nevirapine LLOQ 15.24 15.06 98.86 2.96 15.60 102.40 3.84
LQC 44.29 45.00 101.60 1.89 45.74 103.28 2.83
MQC 738.19 748.98 101.46 0.86 747.47 101.26 2.24
HQC 1845.48 1878.40 101.78 1.17 1864.04 101.01 2.59
Table 4 Matrix effects for analytes in eight different lots of human plasma
Analyte LQC analyte average
peak area in absence
of matrix
LQC analyte average





% CV HQC analyte average
peak area in absence
of matrix
HQC analyte average






Lamivudine 33,007 31,718 96.09 1.43 1,281,899 1,332,156 103.92 2.09
Zidovudine 6848 6721 98.15 4.24 273,050 283,906 103.98 1.68
Nevirapine 57,547 54,476 94.66 1.21 2,070,858 2,112,144 101.99 1.66
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a) Stability in aqueous solution
i. Short-term stock solution stability (STSS)
MQC concentration of each analyte was prepared
by dilution of respective stock solution and stored
at 25 °C for 24 h. Six replicate injections were
given for MQC sample. No significant differences
were noticed when these results were compared
with those obtained from the freshly prepared
MQC samples indicating that all analytes were
stable at 25 °C (Table 5). Accepted criteria for the
ratio of mean response for stability samples
should be between 90 and 110 %.
ii. Long-term stock solution stability (LTSS)
Aqueous MQC sample of each analyte, prepared
by dilution from respective stock solution which
was stored at 2–8 °C for 40 days was injected.
Mean area response of MQC of stored stock
solution was then compared against MQC from
Table 5 Stability studies of aqueous stock solutions of analytes
Stability
check




STSS (25 h) Lamivudine MQC 536,739 535,814 1.07 99.36
Zidovudine MQC 121,203 121,766 1.07 99.49
Nevirapine MQC 907,909 912,565 1.16 99.44
LTSS (40 days) Lamivudine MQC 551,425 550,174 1.20 100.32
Zidovudine MQC 125,575 124,388 1.68 100.95
Nevirapine MQC 928,136 915,249 1.36 101.23
an = 6
Table 6 Stability studies of analytes in human plasma




Lamivudine Bench top (7.0 h) LQC 27.53 27.76 2.34 100.84
HQC 1146.90 1161.87 1.77 102.31
Freeze thaw (4 cycles) LQC 27.53 28.16 2.52 102.26
HQC 1146.90 1155.10 2.97 101.71
In-auto-sampler (22 h) LQC 27.53 27.95 4.44 101.50
HQC 1146.90 1159.58 1.63 102.11
Wet extract (7 h) LQC 27.53 27.72 2.76 100.69
HQC 1146.90 1150.12 1.65 101.27
Zidovudine Bench top (7.0 h) LQC 29.84 28.43 3.38 97.79
HQC 1243.43 1212.32 2.06 100.06
Freeze thaw (4 cycles) LQC 29.84 30.02 1.50 103.24
HQC 1243.43 1206.04 1.71 99.54
In-auto-sampler (22 h) LQC 29.84 28.97 5.08 99.66
HQC 1243.43 1212.50 1.43 100.07
Wet extract (7 h) LQC 29.84 28.32 5.96 97.40
HQC 1243.43 1210.84 2.51 99.94
Nevirapine Bench top (7.0 h) LQC 44.29 45.33 2.18 101.73
HQC 1845.48 1821.13 1.08 102.24
Freeze thaw (4 cycles) LQC 44.29 46.25 2.82 103.80
HQC 1845.48 1816.07 1.34 101.96
In-auto-sampler (22 h) LQC 44.29 45.38 3.30 101.84
HQC 1845.48 1829.70 1.44 102.73
Wet extract (7 h) LQC 44.29 44.48 1.54 99.81
HQC 1845.48 1795.11 1.76 100.78
an = 6
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freshly prepared stock solution. Mean percent
stability (100.83) was well within accepted limit
(90–110 %). This indicated the stability of each
analyte solution for 40 days at 2–8 °C (Table 5).
b) Stability in human plasma
i. Bench-top stability
Six aliquots of each analyte in human plasma
(at LQC and HQC concentrations) from −20 °C
were allowed to thaw unassisted at room
temperature (25 °C) for 7 h and processed along
with a set of freshly prepared calibration
standards as well as LQC and HQC samples. The
stability for LQC and HQC samples of each
analyte were found in the range of 97.79–
101.73 % and 100.06–102.31 %, respectively.
ii. Freeze thaw stability
After four freeze thaw cycles, the stability for
LQC and HQC samples of each analyte were in
the range of 102.26–103.80 % and 99.54–
101.96 %, respectively.
iii. In-injector stability
The stability for LQC and HQC samples of each
analyte kept in auto-sampler at 10 °C for 22 h
were in the range of 99.66–101.84 % and 100.07–
102.73 %, respectively.
iv. Wet extract stability
The stability for LQC and HQC samples of each
analyte after 7 h at 25 °C were in the range of
97.40–100.69 % and 99.94–101.27 %, respectively.
Accepted range for all the abovementioned
stability studies is that the mean concentration
for stability samples should be 85–115 % of the
mean concentration of freshly prepared samples.
Thus, all the analytes were stable during the
analysis process. Results of the stability
evaluations were presented in Table 6.
Extended precision and accuracy run
Extended precision and accuracy run was performed by
processing and analyzing one set of CC and 40 sets of
LQC and HQC as a batch (total 90 samples). Results of
precision and accuracy were presented in Table 7. The
precisions for lamivudine, zidovudine, and nevirapine
were 2.72, 4.71, and 2.28 % for LQC and 2.52, 2.12, and
2.47 % for HQC, respectively. The accuracies were
97.65, 97.42, and 101.25 % for LQC and 100.55, 97.46,
and 98.35 % for HQC, respectively.
Conclusions
A fast, sensitive, and specific LC–MS/MS method for
simultaneous determination of lamivudine, zidovudine,
and nevirapine in human plasma was developed and
validated. This is the first method using column coup-
ling technique to estimate simultaneously these three
drugs in human plasma. It also utilizes a more selective
solid phase extraction technique, offering consistent and
reproducible recoveries for all three analytes with insig-
nificant interference and matrix effect. Moreover, this is
the first method where labeled internal standards were
used. As per FDA guidelines, internal standard should
preferably be identical to the analyte (US Food and Drug
Administration, Center for Drug Evaluation and Re-
search (CDER) 2001). By using 100 μL-plasma samples,
the lower limits of quantification were achieved. It dem-
onstrates that the method is reproducible, sensitive, and
suitable for high-throughput sample analysis. This
method has the potential to be useful for bioequivalence
studies and routine therapeutic drug monitoring.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SR designed the experiment. LT, SK. and NN were involved in the method
development and validation. AM prepared the manuscript after the analysis
of the results, and ST reviewed the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
The authors thank the management of Norwich Clinical Services for
providing the opportunity to complete the project.
Received: 21 March 2016 Accepted: 26 July 2016
References
Chi J, Jayewardene AL, Stone JA, Aweeka FT. An LC–MS–MS method for the
determination of nevirapine, a non-mucleoside reverse transcriptase
inhibitor, in human plasma. J Pharm Biomed Anal. 2003;31:953–9.
De Clercq E. New developments in anti-HIV chemotherapy. Biochim Biophys
Acta. 2002;1587:258–75.
Elase L, Watson V, Tjia J, Hughes A, Siccardi M, Khoo S, Back D. Validation of a
rapid and sensitive high-performance liquid chromatography-tandem mass
spectrometry (HPLC–MS/MS) assay for the simultaneous determination of
existing and new antiretroviral compounds. J Chromatogr B Analyt Technol
Biomed Life Sci. 2010;878:1455–65.
Font E, Rosario O, Santana J, Garcia H, Sommadossi JP, Rodriguez JF.
Determination of zidovudine triphosphate intra-cellular concentrations in
peripheral blood mononuclear cells from human immunodeficiency virus-
infected individuals by tandem mass spectrometry. Antimicrob Agents
Chemother. 1999;43:2964–8.
Gallant JE. Initial therapy of HIV infection. J Clin Virol. 2002;25:317–33.
Gehrig AK, Mikus G, Haefeli WE, Burhenne J. Electrospray tandem mass
spectroscopic characterization of 18 antiretroviral drugs and simultaneous
quantification of 12 antiretrovirals in plasma. J Rapid Commun Mass
Spectrom. 2007;21:2704–16.










Lamivudine LQC 27.53 26.88 97.65 2.72
HQC 1146.90 1153.16 100.55 2.52
Zidovudine LQC 29.84 29.07 97.42 4.71
HQC 1243.43 1211.79 97.46 2.12
Nevirapine LQC 44.29 44.85 101.25 2.28
HQC 1845.48 1815.04 98.35 2.47
Reddy et al. Journal of Analytical Science and Technology  (2016) 7:17 Page 9 of 10
Goodman and Gillman’s. The pharmacological basis of therapeutics. 11th ed.
New York: McGraw Hill; 2001.
Kenney KB, Wring SA, Carr RM, Wells GN, Dunn JA. Simultaneous determination
of zidovudine and lamivudine in human serum using HPLC with tandem
mass spectrometry. J Pharm Biomed Anal. 2000;22:967–83.
Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC,
Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic
hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med.
1998;339:61–8.
Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P,
Sudre P, Flepp M, Furrer H, Francioli P, Weber R. Clinical progression and
virological failure on highly active antiretroviral therapy in HIV-1 patients: a
prospective cohort study: Swiss HIV cohort study. Lancet. 1999;353:863–8.
Mistri HN, Jangid AG, Pudage A, Gomes N, Sanyal M, Shrivastav P. High
throughput LC–MS/MS method for simultaneous quantification of
lamivudine, stavudine and nevirapine in human plasma. J Chromatogr B
Analyt Technol Biomed Life Sci. 2007;853:320–32.
Murali Krishna M, Nageswara Rao P, Jaswanth Kumar I, Laxminarayana B, Seshagiri
Rao JVLN. Simultaneous quantitation of lamivudine, zidovudine and
nevirapine in human plasma by liquid chromatography–tandem mass
spectrometry and application to a pharmacokinetic study. Acta
Pharmaceutica Sinica B. 2012;2:472–80.
Pereira AS, Kenney KB, Cohen MS, Hall JE, Eron JJ, Tidwell RR, Dunn JA.
Simultaneous determination of lamivudine and zidovudine concentrations in
human seminal plasma using high-performance liquid chromatography and
tandem mass spectrometry. J Chromat B Biomed Sci Appl. 2000;742:173–83.
Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL,
Leedom JM, Groopman JE, Mildvan D, Hirsch MS. The toxicity of
azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-
related complex. A double-blind, placebo-controlled trial. N Engl J Med.
1987;317:192–7.
US Food and Drug Administration, Center for Drug Evaluation and Research (CDER).
Guidance for industry: bioanalytical method validation. 2001. Available:
http://www.fda.gov/downloads/Drugs/%E2%80%A6/Guidances/ucm070107.pdf.
Valluru Rajani K, Phani Bhushana RB, Ravi Kumar B, Sreekanth K, Naveen Babu K.
High throughput LC–MS/MS method for simultaneous determination of
zidovudine, lamivudine and nevirapine in human plasma. J Chromatogr B.
2013;921–922:9–14.
Van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P,
Lalloo UG, Van der Westhuizen IP, Malan DR, Johnson MA, Santos BR,
Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F,
Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R,
Robinson P, Wit FW, Lange JM. Comparison of first-line antiretroviral therapy
with regimens including nevirapine, efavirenz, or both drugs, plus stavudine
and lamivudine: a randomised open-label trial, the 2NN Study. Lancet.
2004;363:1253–63.
Zhou L, Cungang D, Qinghua G, Zhen Z, Xiaojin Z, Xiaofen L. Simultaneous
determination of lamivudine, stavudine and nevirapine in human plasma by
LC–MS/MS and its application to pharmacokinetic study in clinic. Biomed
Chroma. 2010;24:926–34.
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Reddy et al. Journal of Analytical Science and Technology  (2016) 7:17 Page 10 of 10
